www.thestandnews.com/personal/一分鐘化學-銀離子殺毒/
Potential toxicology considerations of nanosilver particles (NSPs), both in vitro (Latin for within the glass) and in vivo (Latin for within the living), are also addressed...NSPs are also an antiviral agent against HIV-1, hepatitis B virus, respiratory syncytial virus, herpes simplex virus type 1, and monkeypox virus. It has been observed that NSPs have higher antiviral activity than silver ions.
There is a limited number of well-controlled studies on the potential toxicities of nanosilver, though these studies tend to suggest that NSPs can induce toxicity in living beings. It should be noted that in vitro conditions are drastically different from in vivo conditions; however, longer-term studies and assessment of NSP toxicity must be conducted so that NSP exposure does not exceed toxic levels.
Ge, L. P. & Li, Q.T. (2014). Nanosilver particles in medical applications: synthesis, performance, and toxicity. International Journal of Nanomedicine, 9, 2399–2407. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037247/
FDA is issuing a final rule establishing that all OTC drug products containing colloidal silver ingredients or silver salts for internal or external use are not generally recognized as safe and effective and are misbranded (貼錯標簽). FDA is issuing this final rule because many OTC drug products containing colloidal silver ingredients or silver salts are being marketed for numerous serious disease conditions and FDA is not aware of any substantial scientific evidence that supports the use of OTC colloidal silver ingredients or silver salts for these disease conditions.
No authors listed (1999).Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule. Federal Register. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10558603
沒有留言:
發佈留言